Skip to search formSkip to main contentSkip to account menu

AG 014699

Known as: AG-014699, AG014699, PARP-1 inhibitor AG014699 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

rucaparib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
[Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
OBJECTIVE To observe the effects of poly(ADP-ribose)polymerase (PARP) inhibitor AG014699 alone and combined with docetaxel (DTX… 
2013
2013
Abstract 3349: Preclinical efficacyof the PARP inhibitor rucaparib (AG014699/PF-01367338) as a monotherapy and incombination with PI3K inhibition.
Poly (ADP-ribose) polymerase (PARP) inhibitors are an emerging class of potential anti-cancer therapeutics currently being… 
2012
2012
349 Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)
2012
2012
Abstract 2540: Identification of factors governing sensitivity of NSCLC cell lines to inhibition of Poly (ADP-Ribose) Polymerase (PARP)
Recently, Poly (ADP Ribose) Polymerase-1 (PARP-1) has been shown to be an important target in subsets of breast and ovarian… 
Review
2011
Review
2011
PARP inhibitors--current status and the walk towards early breast cancer.
2011
2011
All PARP inhibitors are not equal: An in vitro mechanistic comparison of PF-01367338 to iniparib.
e13576 Background: PARP is a key enzyme involved in base-excision repair. Pre-clinically it has been shown that BRCA1/2 deficient… 
Review
2011
Review
2011
Abstract PL04-02: Synthetic lethality: Targeting DNA repair mechanisms in clinical trials
Epithelial carcinomas are in general diseases occurring as a result of the acquisition of and selection for multiple mutations in… 
2008
2008
Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic…
2006
2006
A phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)
2005
2005
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)